Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.

ABSTRACT: Multiple myeloma is incurable once osteolytic lesions have seeded at skeletal sites, but factors mediating this deadly pathogenic advance remain poorly understood. Here, we report evidence of a major role for the cell adhesion molecule CD166, which we discovered to be highly expressed in multiple myeloma cell lines and primary bone marrow cells from patients. CD166⁺ multiple myeloma cells homed more efficiently than CD166^- cells to the bone marrow of engrafted immunodeficient NSG mice. CD166 silencing in multiple myeloma cells enabled longer survival, a smaller tumor burden, and less osteolytic lesions, as compared with mice bearing control cells. CD166 deficiency in multiple myeloma cell lines or CD138⁺ bone marrow cells from multiple myeloma patients comp

SUBMITTER: Xu L 

PROVIDER: S-EPMC5135585 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature